CTLA4 and malignant colon neoplasm: Immunotherapy drugs (PD1/PD-L1 blocker and CTLA-4 blocker) have been shown to improve the prognosis of colon cancer patients (Yaghoubi et al., 2019; Ben et al., 2021).